期刊文献+

2例急性髓细胞性白血病(AML-M_2型)伴t(8;21)治疗后复发的经验和教训

下载PDF
导出
出处 《中国小儿血液与肿瘤杂志》 CAS 2009年第2期87-89,共3页 Journal of China Pediatric Blood and Cancer
  • 相关文献

参考文献7

  • 1Mrozek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program, 2006:169-177.
  • 2Nanri T, Matsuno N, Kawakita T, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t ( 8 ; 21 ) ( q22 ; q22). Leukemia, 2005 ;19 : 1361-1366.
  • 3Perea G, Lasa A, Aventin A, Domingo A,et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [ t ( 8 ; 21 ) and inv ( 16 ) ]. Leukemia, 2006 ;20 : 87-94.
  • 4Shimada A, Taki T, Tabuchi K, et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t (8 ;21 ) : a study of the Japanese Childhood AML Cooperative Study Group. Blood, 2006 ; 107 : 1806-1809.
  • 5Lane S, Saal R, Mollee P, Jones M, et al. A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. Leuk Lymphoma, 2008 ;49:517-523.
  • 6Narimatsu H, Iino M, Ichihashi T,et al. Clinical significance of minimal residual disease in patients with t(8 ;21 )acute myeloid leukemia in Japan. Int J Hematol, 2008;88(2) : 154-8.
  • 7Lange B J, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the Children 's oneology group. Blood, 2008;111(3) :1044-532.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部